- Home
- DOUG vs ABOS Comparison
DOUG vs ABOS Comparison
Compare DOUG & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DOUG | ABOS |
|---|---|---|
| Founded | 1911 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building operators | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 162.3M | 182.0M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | DOUG | ABOS |
|---|---|---|
| Price | $1.74 | $2.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | ★ 472.1K | 298.2K |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 118.68 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $955,578,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.94 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.53 | $0.97 |
| 52 Week High | $3.20 | $3.60 |
Technical Indicators
Market Signals| Indicator | DOUG | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 41.57 | 46.59 |
| Support Level | $1.55 | $2.24 |
| Resistance Level | $1.84 | $3.02 |
| Average True Range (ATR) | 0.13 | 0.14 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 4.44 | 32.73 |
Price Performance
Historical ComparisonAbout DOUG Douglas Elliman Inc.
Douglas Elliman Inc is engaged in the real estate services business and seeks to acquire or invest in additional real estate services businesses. The Company also offers, through its subsidiaries and ventures, development marketing services and ancillary services, including mortgage, title, and escrow services. It generates revenue from commissions and other brokerage income, property management, and other ancillary services.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.